FINAL RESULTS OF PHASE II RANDOMIZED TRIAL OF AZACITIDINE VERSUS SUPPORT TREATMENT IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROME WITHOUT THE 5Q DELETION

被引：1
|
作者：
Sanchez-Garcia, J. [1 ]
Falantes, J. [2 ]
Medina, A. [3 ]
Hernandez-Mohedo, F. [4 ]
Torres-Sabariego, A. [5 ]
Bailen, A. [6 ]
Sole, M.
Casano, J. [1 ]
Calderon, C.
Hermosin, L. [7 ]
Vahi, M. [5 ]
Serrano, J. [1 ]
机构：
[1] Univ Cordoba, Hematol, Reina Sofia Hosp, IMIBIC, Cordoba, Spain
[2] Univ Hosp Virgen Rocio, Hematol, Seville, Spain
[3] Hosp Costa Sol, Hematol, Marbella, Spain
[4] Hosp Costa Sol, Hematol, Granada, Spain
[5] Hosp Virgen Valme, Hematol, Seville, Spain
[6] Hosp Univ Carlos Haya, Hematol, Malaga, Spain
[7] Hosp Jerez, Hematol, Jerez de la Frontera, Spain
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30115-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
114
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [31] Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/- Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone
    Boehrer, Simone
    Beyne-Rauzy, Odile
    Prebet, Thomas
    Park, Sophie
    Guerci, Agnes
    Stamatoulas, Aspasia
    Chaury, M. P.
    Jernival, Tony
    Sanhes, Laurence
    Tertian, Gerard
    Cheze, Stephane
    Lim, Eng-Mong
    Choufi, Bachra
    Caillot, Denis
    Wattel, E.
    Delaunay, Jacques
    Legros, Laurence
    Chermat, Fatiha
    Isnard, Francoise
    Cambier, N.
    Slama, Borhane
    Roy, Lydia
    Damaj, Gandhi
    Raffoux, Emmanuel
    Dreyfus, Francois
    Recher, Christian
    Vey, Norbert
    Chevret, Sylvie
    Fenaux, Pierre
    Gardin, Claude
    BLOOD, 2010, 116 (21) : 784 - 784
  • [32] Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis
    Lian, Xin-yue
    Zhang, Zhi-hui
    Deng, Zhao-qun
    He, Pin-fang
    Yao, Dong-ming
    Xu, Zi-jun
    Wen, Xiang-mei
    Yang, Lei
    Lin, Jiang
    Qian, Jun
    PLOS ONE, 2016, 11 (11):
  • [33] Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
    Ades, Lionel
    Boehrer, Simone
    Prebet, Thomas
    Beyne-Rauzy, Odile
    Legros, Laurence
    Ravoet, Christophe
    Dreyfus, Francois
    Stamatoullas, Aspasia
    Chaury, Marie Pierre
    Delaunay, Jacques
    Laurent, Guy
    Vey, Norbert
    Burcheri, Sara
    Mbida, Rose-Marie
    Hoarau, Natacha
    Gardin, Claude
    Fenaux, Pierre
    BLOOD, 2009, 113 (17) : 3947 - 3952
  • [34] Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
    Schuler, E.
    Giagounidis, A.
    Haase, D.
    Shirneshan, K.
    Buesche, G.
    Platzbecker, U.
    Nolte, F.
    Goetze, K.
    Schlenk, R. F.
    Ganser, A.
    Letsch, A.
    Braulke, F.
    Luebbert, M.
    Bug, G.
    Schafhausen, P.
    Bacher, U.
    Gattermann, N.
    Wulfert, M.
    Haas, R.
    Germing, U.
    LEUKEMIA, 2016, 30 (07) : 1580 - 1582
  • [35] Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)
    E Schuler
    A Giagounidis
    D Haase
    K Shirneshan
    G Büsche
    U Platzbecker
    F Nolte
    K Götze
    R F Schlenk
    A Ganser
    A Letsch
    F Braulke
    M Lübbert
    G Bug
    P Schafhausen
    U Bacher
    N Gattermann
    M Wulfert
    R Haas
    U Germing
    Leukemia, 2016, 30 : 1580 - 1582
  • [36] Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: Results from a randomized clinical trial
    Revicki, Dennis A.
    Brandenburg, Nancy A.
    Muus, Petra
    Yu, Ren
    Knight, Robert
    Fenaux, Pierre
    LEUKEMIA RESEARCH, 2013, 37 (03) : 259 - 265
  • [37] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Raza, Azra
    Galili, Naomi
    Mulford, Deborah
    Smith, Scott E.
    Brown, Gail L.
    Steensma, David P.
    Lyons, Roger M.
    Boccia, Ralph
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Mesa, Ruben A.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [38] Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
    Azra Raza
    Naomi Galili
    Deborah Mulford
    Scott E Smith
    Gail L Brown
    David P Steensma
    Roger M Lyons
    Ralph Boccia
    Mikkael A Sekeres
    Guillermo Garcia-Manero
    Ruben A Mesa
    Journal of Hematology & Oncology, 5
  • [39] Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Borthakur, Gautam M.
    Naqvi, Kiran
    Daver, Naval G.
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Andreeff, Michael
    Alvarado, Yesid
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [40] Low frequency of the glutathione-S-transferase T1-null genotype in patients with primary myelodysplastic syndrome and 5q deletion
    Stavropoulou, C.
    Sambani, C.
    Rigana, H.
    Georgakakos, V. N.
    Voutsinas, G.
    Manola, K. N.
    Pantelias, G. E.
    Makropoulos, V.
    LEUKEMIA, 2008, 22 (08) : 1643 - 1646
12345